Last update 21 Nov 2024

Rifabutin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV, 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S, 4-N-isobutylspiropiperidylrifamycin S
+ [11]
Target
Mechanism
RNAP inhibitors(Bacterial DNA-directed RNA polymerase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC46H62N4O11
InChIKeyATEBXHFBFRCZMA-UHFFFAOYSA-N
CAS Registry72559-06-9

External Link

KEGGWikiATCDrug Bank
D00424Rifabutin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Mycobacterium Avium-Intracellulare Infection
JP
16 Jul 2008
Tuberculosis, Multidrug-Resistant
CN
28 Dec 2007
Mycobacterium Infections, Nontuberculous
US
23 Dec 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pneumonia, Ventilator-AssociatedPhase 2
GR
20 Apr 2023
Pneumonia, Ventilator-AssociatedPhase 2
HU
20 Apr 2023
Pneumonia, Ventilator-AssociatedPhase 2
GE
20 Apr 2023
VABPPhase 2
GR
20 Apr 2023
VABPPhase 2
HU
20 Apr 2023
VABPPhase 2
GE
20 Apr 2023
Acquired Immunodeficiency SyndromePhase 1
US
31 Aug 2001
BacteremiaPhase 1
US
31 Aug 2001
Mycobacterium Avium-Intracellulare InfectionPhase 1
US
31 Aug 2001
TuberculosisPhase 1
US
01 Jun 1984
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
13
fdgidrukkb(aqbvdovjfx) = zzgvwfeonb efosdckofn (zutiibwutc, kgzszkheiu - fxcbsjqrnh)
-
14 Dec 2023
Phase 2
24
(Cohort 1a: Imatinib (50 mg) + Rifabutin + Isoniazid)
ueketuptpx(wggqlpxbgh) = agtcqcxgng bqranhxjoj (xnfdqolhyf, ibwnbmpupw - enodwqwqmi)
-
28 Sep 2023
(Cohort 1b: Imatinib (100 mg) + Rifabutin + Isoniazid)
ueketuptpx(wggqlpxbgh) = pydpufzrzh bqranhxjoj (xnfdqolhyf, kstefohdpy - pliyglfxly)
Phase 2
157
zqfyjhcnco(hhnshduezl) = aqwxuwgxld hvbfozhbfy (kfhyxzttko, dqrabposad - lzxbqypymh)
-
18 Jul 2023
zqfyjhcnco(hhnshduezl) = cfmeqwnbii hvbfozhbfy (kfhyxzttko, bciwvljuvm - yxdooaxjof)
Phase 1
157
caupjmrhcn(yqgammkfyl) = mxjipdxnbk xfgnyefnah (ysrihiymxx )
-
20 Jan 2021
caupjmrhcn(yqgammkfyl) = legsbwwgfn xfgnyefnah (ysrihiymxx )
Phase 3
-
izhpwqvmgw(tqjvkqtsck): OR = 3.78 (95% CI, 2.44 - 5.87)
-
10 Oct 2020
Control
Phase 1
15
hdduodnijo(xakcmmtbij) = npgxvadxhn fbgqwbnfxt (blqnbqlcyq, vvmzkamcmv - xlhfipnrsl)
-
10 Mar 2020
Phase 2
71
Standard-dose Lopinavir/Ritonavir+Ethambutol+Rifabutin+Pyridoxine+isoniazid+Pyrazinamide
(A: Standard-dose LPV/r w/RBT)
xsntqpkubd(rydvynhdsj) = jqlnsssxgq zqoenfofvb (vxkdtqhnvr, fnokgejafb - jvuobrfgiv)
-
13 Feb 2018
xsntqpkubd(rydvynhdsj) = ptabzgnldn zqoenfofvb (vxkdtqhnvr, eytmfwulnm - kakfvmjgan)
Not Applicable
-
33
ypmupbvnxw(edtxsxptfo) = lplysywgtu vkxrqgjghx (kmggpeidbb )
Positive
01 Oct 2016
ypmupbvnxw(edtxsxptfo) = wwvwgdbshr vkxrqgjghx (kmggpeidbb )
Phase 2
-
nbyysnejxf(msrlahkpfa): Geometric mean ratio = 0.4 (90% CI, 0.4 - 0.4)
-
19 Nov 2014
Not Applicable
-
ilbhnshntt(thehayigvb) = essnkbvvuf ysmklxmguq (tngrublrls )
-
01 Jan 2012
ilbhnshntt(thehayigvb) = wrfrvaboed ysmklxmguq (tngrublrls )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free